argininerich
cellpenetr
peptid
cpp
promis
transport
intracellular
deliveri
antisens
morpholino
oligom
pmo
determin
effect
larginin
darginin
nona
amino
acid
cellular
uptak
splicecorrect
activ
cellular
toxic
serum
bind
insert
acid
x
balanin
b
residu
oligoarginin
r
decreas
cellular
uptak
increas
splicecorrect
activ
result
compound
greater
increas
sequenc
contain
x
residu
cellular
toxic
observ
conjug
km
km
conjug
xs
exhibit
timeand
concentrationdepend
toxic
substitut
larginin
darginin
increas
uptak
splicecorrect
activ
high
concentr
serum
significantli
decreas
uptak
splicecorrect
activ
oligoarginin
conjug
much
less
effect
conjug
contain
x
b
summari
incorpor
xb
oligoarginin
enhanc
antisens
activ
serumbind
profil
toxic
xbcontain
conjug
affect
number
xs
treatment
time
concentr
activ
stabl
less
toxic
cpp
design
optim
posit
number
r
dr
x
b
residu
stericblock
antisens
oligonucleotid
ao
consid
potenti
therapeut
genet
diseas
duchenn
muscular
dystrophi
dmd
bthalassemia
potenti
realiz
howev
ao
must
effect
deliv
cell
nuclei
cation
lipoplexor
peibas
transfect
method
use
deliv
charg
ao
suitabl
deliveri
uncharg
ao
phosphorodiamid
morpholino
oligom
pmo
figur
peptid
nucleic
acid
pna
conjug
pmo
short
cpp
good
method
enhanc
cytoplasm
nuclear
deliveri
pmo
conjug
simpl
use
short
peptid
ao
conjug
easili
manufactur
character
qualitycontrol
manner
exampl
wellstudi
conjug
includ
tat
oligoarginin
peptid
import
consider
design
effect
cpp
includ
abil
deliv
ao
effici
stabil
live
system
toxic
report
tat
oligoarginin
peptid
stabl
human
serum
therefor
illsuit
vivo
applic
oligoarginin
peptid
incorpor
nona
amino
acid
proven
superior
oligoarginin
alon
cpp
contain
acid
x
balanin
b
stabl
human
serum
tat
oligoarginin
peptid
conjug
rxr
shown
effici
correct
premrna
missplic
inhibit
replic
mous
hepat
viru
vivo
oligoarginin
peptid
addit
rxr
conjug
shown
caus
effect
exon
skip
muscl
cell
dmd
dog
human
muscl
explant
mdx
mice
well
inhibit
replic
variou
virus
cell
cultur
mice
studi
help
make
clear
unnatur
amino
acid
confer
enhanc
stabil
activ
therefor
improv
potenti
cpp
deliv
therapeut
pmo
pursuit
cpp
improv
characterist
carri
structureact
relationship
studi
investig
effect
unnatur
amino
acid
insert
oligoarginin
peptid
cellular
deliveri
nuclear
antisens
activ
toxic
serumbind
characterist
result
conjug
unnatur
amino
acid
studi
x
b
darginin
r
chose
studi
x
amino
acid
base
success
rxr
cpp
sever
studi
shown
previou
paragraph
b
r
amino
acid
chosen
good
enzymat
stabil
cpp
oligoarginin
sequenc
r
r
ii
sequenc
rxr
rx
rb
repeat
well
variou
combin
thereof
iii
sequenc
contain
darginin
r
rx
rxr
rxr
rb
conjug
evalu
rel
cellular
uptak
determin
flow
cytometri
b
antisens
activ
determin
splice
correct
assay
c
cellular
toxic
determin
mtt
cell
viabil
propidium
iodid
membran
integr
hemolysi
assay
well
microscop
imag
cpp
nomenclatur
sequenc
list
tabl
chemic
structur
pmo
rx
shown
figur
antisens
pmo
cct
ctt
acc
tca
gtt
aca
design
target
bthalassem
mutant
splice
site
present
human
bglobin
intron
positivereadout
antisens
activ
assay
system
describ
result
section
synthesi
pmo
describ
previous
cpp
use
standard
fmoc
chemistri
perform
avi
biopharma
achiev
puriti
determin
hplc
mass
spectrometri
analysi
conjug
cpp
pmo
amid
linker
describ
previous
follow
addit
purif
step
remov
nonconjug
peptid
sampl
load
sourc
resin
amersham
bioscienc
pittsburgh
pa
ml
biorad
hercul
ca
column
mlmin
run
buffer
mm
na
hpo
acetonitril
ph
purifi
fraction
buffer
gradient
buffer
b
nacl
mm
na
hpo
acetonitril
ph
min
use
biorad
biolog
low
pressur
chromatographi
system
desir
faction
desalt
method
describ
previous
hplc
ms
analys
reveal
final
product
contain
cpp
conjug
fulllength
pmo
balanc
compos
cpp
conjug
incomplet
pmo
sequenc
nonconjug
fulllength
incomplet
pmo
hela
cell
line
obtain
gene
tool
llc
philomath
human
liver
cell
line
american
type
cultur
collect
atcc
manassa
va
cell
cultur
rpmi
medium
supplement
mm
lglutamin
uml
penicillin
fetal
bovin
serum
fb
hyclon
ogden
ut
humidifi
atmospher
contain
co
treatment
carri
optimem
medium
gibco
inc
carlsbad
ca
without
fb
cell
uptak
assay
cell
seed
h
prior
treatment
plate
cellswel
cell
treat
mm
fluoresceintag
conjug
h
treatment
cell
wash
ml
rxrxrxrxrxrxrxb
rx
rxrxrxrxrxb
rx
rxrxrxb
rxr
rxrrxrrxrrxrxb
rxr
rxrrxrrxrrxrxb
rxr
rxrrxrrxrrxrxb
rb
rbrbrbrbrbrbrbrbb
rb
rbrbrbrbrbrbrbrbb
rb
rbrbrbrbrbrbrbb
rb
rbrbrbrbrbb
rb
rbrbrbb
sequenc
peptid
written
n
c
terminu
r
arginin
r
darginin
x
acid
b
balanin
peptid
acetyl
group
nterminu
carboxyl
group
cterminu
cell
viabil
assay
microscopi
cell
seed
h
treatment
plate
cellwel
treat
conjug
microscop
phase
imag
treat
cell
visual
nikon
diaphot
invert
microscop
melvil
ny
captur
olympu
digit
camera
process
magnafir
softwar
optron
goleta
ca
imag
cell
cell
viabil
determin
methylthiazoletetrazolium
assay
mtt
sigma
st
loui
mo
assay
mtt
solut
mgml
ad
treatment
medium
final
concentr
mgml
incub
h
media
well
replac
dmso
contain
hcl
incub
min
absorb
measur
nm
percent
cell
viabil
determin
normal
absorb
treat
sampl
mean
untreat
sampl
propidium
iodid
membran
integr
assay
cell
seed
h
treatment
plate
cellswel
cell
treat
remov
medium
wash
ml
pb
incub
medium
contain
conjug
treatment
medium
collect
tube
cell
wash
pb
treat
ml
trypsin
min
trypsin
neutral
ml
serum
contain
medium
cell
transfer
tube
contain
previous
collect
treatment
medium
pellet
centrifug
min
wash
pb
resuspend
ml
mgml
propidium
iodid
pi
pb
cell
incub
min
analyz
beckman
coulter
cytomet
eventssampl
collect
hemolyt
activ
conjug
determin
fresh
rat
blood
accord
method
describ
elsewher
cellular
uptak
conjug
investig
use
carboxyfluoresceintag
pmo
pmof
flow
cytometri
chose
mm
treatment
concentr
none
conjug
caus
detect
cytotox
concentr
demonstr
mtt
pi
uptak
assay
treat
conjug
cell
treat
trypsin
remov
membranebound
conjug
found
heparin
sulfat
wash
step
prior
trypsin
treatment
remov
addit
membranebound
conjug
caus
cellular
toxic
data
shown
therefor
trypsin
treatment
step
use
studi
determin
effect
serum
cellular
uptak
variou
conjug
uptak
evalu
assay
carri
medium
contain
variou
concentr
absenc
serum
cellular
uptak
conjug
increas
number
arginin
decreas
x
andor
b
residu
insert
figur
b
oligoarginin
r
mean
fluoresc
mf
nearli
higher
produc
r
indic
differ
singl
arginin
make
substanti
differ
biolog
properti
cpp
insert
x
b
residu
r
sequenc
reduc
mf
r
rx
rxr
rb
respect
figur
number
rx
rb
repeat
affect
cellular
uptak
conjug
fewer
rx
rb
repeat
gener
lower
mf
figur
addit
serum
medium
caus
decreas
uptak
r
r
conjug
increas
uptak
conjug
contain
rx
rb
rxr
motif
figur
c
serum
reduc
mf
r
r
respect
increas
mf
rx
rxr
rb
respect
differ
statist
signific
figur
howev
higher
serum
concentr
decreas
uptak
rxr
figur
arginin
stereochemistri
versu
l
littl
effect
uptak
conjug
compar
mf
r
rb
rx
respect
disom
conjug
r
rb
rx
found
signific
differ
pair
shown
figur
rx
rx
pair
nuclear
antisens
activ
effect
conjug
determin
previous
describ
splice
correct
assay
consid
reliabl
method
assess
nuclear
antisens
activ
stericblock
ao
assay
util
abil
stericblock
ao
block
splice
site
creat
mutat
order
restor
normal
splice
luciferas
code
sequenc
interrupt
human
bglobin
thalassem
intron
carri
mutat
splice
site
nucleotid
hela
cell
stabli
transfect
plasmid
therefor
name
cell
system
stericblock
ao
must
present
cell
nucleu
splice
correct
occur
advantag
system
includ
posit
readout
high
signaltonois
ratio
system
rel
effici
variou
cpp
deliv
ao
sequenc
appropri
splicecorrect
cell
nuclei
easili
compar
oligoarginin
rx
rxr
rb
panel
cpp
conjug
highest
nuclear
antisens
activ
rxr
rx
figur
b
show
luciferas
activ
normal
protein
cell
treat
variou
conjug
mm
h
concentr
rx
rxr
effect
conjug
test
differ
promin
serumcontain
medium
mm
mm
cell
treat
mm
either
conjug
luciferas
activ
background
remain
conjug
yield
background
figur
mm
conjug
gener
higher
luciferas
activ
figur
cellular
uptak
conjug
cell
treat
carboxyfluoresceintag
pmo
conjug
cpp
optimem
without
serum
h
follow
flow
cytometri
analysi
data
present
mean
fluoresc
mf
ae
sd
six
data
point
two
independ
experi
cell
treat
mm
r
r
rxr
rx
rb
conjug
b
cell
treat
mm
rx
rx
rx
rb
rb
rb
conjug
absenc
serum
c
cell
treat
mm
rxr
r
media
contain
serum
cell
treat
rx
rx
media
contain
serum
mm
rx
rxr
effect
follow
rb
figur
figur
show
mm
activ
rx
rb
conjug
decreas
number
rx
rb
repeat
cpp
decreas
peptid
rx
rb
repeat
rx
rx
rb
rb
gener
much
lower
luciferas
activ
repeat
number
posit
x
residu
shown
rb
less
activ
rxr
rx
investig
effect
number
posit
x
residu
activ
conjug
eleven
conjug
contain
xs
compar
figur
gener
cpp
contain
higher
number
xs
higher
activ
mm
rx
x
residu
highest
activ
follow
rxr
x
residu
conjug
fewer
xs
lower
activ
mm
three
conjug
contain
rx
x
residu
highest
activ
suggest
posit
x
residu
affect
activ
larginin
versu
darginin
arginin
stereochemistri
littl
effect
nuclear
activ
r
rb
conjug
affect
rx
figur
replac
eight
larginin
residu
r
rb
darginin
residu
chang
luciferas
activ
gener
mm
figur
b
howev
replac
caus
small
statist
signific
decreas
activ
rx
mm
p
mm
p
figur
serum
effect
activ
effect
serum
antisens
activ
conjug
depend
cpp
sequenc
shown
figur
addit
serum
medium
decreas
activ
conjug
r
r
increas
activ
conjug
contain
rxr
rx
rb
repeat
addit
serum
nearli
doubl
luciferas
activ
rxr
rx
rb
mm
figur
studi
effect
rxr
serum
activ
almost
doubl
serum
concentr
increas
gradual
decreas
serum
concentr
increas
activ
similar
serum
still
significantli
background
profil
also
observ
mm
rxr
treatment
unlik
rxr
luciferas
activ
r
r
data
shown
decreas
serum
concentr
increas
approxim
reduct
serum
activ
serum
r
r
display
detect
activ
mm
regardless
serum
concentr
data
shown
cellular
toxic
variou
conjug
determin
mttsurviv
propidium
iodin
pi
exclus
hemolysi
assay
microscop
imag
mtt
pi
exclus
assay
measur
metabol
activ
membran
integr
cell
respect
hemolysi
assay
determin
compat
blood
microscop
imag
use
verifi
mtt
result
observ
gener
health
cell
mtt
assay
cell
treat
concentr
rang
mm
h
shown
figur
conjug
except
rx
rxr
toxic
mm
mm
rx
rxr
conjug
exhibit
toxic
higher
concentr
reduc
cell
viabil
concentrationdepend
manner
rx
toxic
rxr
figur
replac
larginin
darginin
r
rb
rxr
chang
viabil
profil
conjug
figur
surprisingli
l
replac
rx
decreas
toxic
cell
viabil
mm
treatment
rx
rx
figur
eight
conjug
contain
fewer
x
residu
inhibit
cell
prolifer
mm
figur
monom
arginin
x
individu
combin
mm
produc
inhibit
cell
prolifer
figur
toxic
conjug
rxr
also
evalu
human
liver
cell
found
rxr
caus
dosedepend
inhibit
cell
prolifer
two
conjug
toxic
mm
highest
concentr
test
studi
data
shown
microscop
imag
sought
verifi
mtt
result
collect
microscop
imag
cell
treat
mm
conjug
imag
correl
well
cell
viabil
data
imag
rx
rx
rxr
rxr
vehicletr
cell
shown
figur
cell
treat
rx
rxr
appear
round
detach
cultur
well
appear
fewer
live
cell
interestingli
cell
treat
rx
appear
normal
morpholog
cell
densiti
replac
one
x
rxr
nuclear
activ
cpppmo
conjug
number
posit
x
residu
cell
treat
conjug
x
residu
see
sequenc
tabl
optimem
medium
serum
h
nuclear
activ
conjug
indic
rel
luciferas
activ
rlu
per
microgram
protein
data
repres
mean
ae
sd
data
point
four
independ
experi
propidium
iodin
exclus
assay
effect
conjug
integr
cell
membran
investig
propidium
iodin
pi
exclus
assay
pi
permeat
unhealthydamag
membran
posit
pi
fluoresc
indic
compromis
cell
membran
rxr
rx
conjug
found
significantli
affect
membran
integr
higher
concentr
mm
test
figur
show
histogram
cell
treat
rxr
mm
h
pi
posit
pi
region
defin
cell
permeabil
ethanol
posit
control
indic
gate
histogram
pi
histogram
shift
pineg
region
piposit
region
longer
incub
indic
conjug
caus
membran
leakag
timedepend
manner
caus
slight
shift
toward
pi
region
produc
distinct
peak
correspond
cell
pi
region
figur
show
histogram
cell
treat
rxr
concentr
mm
h
signific
pi
uptak
concentr
mm
higher
concentr
pi
popul
appear
percentag
pi
cell
increas
treatment
concentr
increas
indic
leak
cell
higher
treatment
concentr
similar
concentrationand
timedepend
pi
uptak
profil
observ
rx
rb
remain
conjug
data
shown
addit
serum
treatment
medium
significantli
reduc
membran
toxic
rxr
figur
rx
conjug
data
shown
hemolysi
assay
rxr
rx
conjug
test
hemolysi
assay
found
compat
red
blood
cell
fresh
rat
red
blood
cell
treat
conjug
mm
pb
background
posit
control
supernat
conjugateand
pbstreat
sampl
small
similar
amount
free
hemoglobin
releas
far
lower
sampl
figur
natur
occur
cpp
tat
peptid
stabl
blood
neither
oligolysineoligoarginin
render
cpp
unfavor
transport
therapeut
ao
reason
one
approach
improv
stabil
would
use
nona
amino
acid
damino
acid
studi
investig
whether
incorpor
acid
x
balanin
b
darginin
r
amino
acid
cpp
would
affect
cellular
deliveri
antisens
activ
toxic
serum
bind
result
conjug
found
conjug
contain
xb
residu
enter
cell
effici
r
r
conjug
consist
previou
find
rxr
conjug
found
cell
surfac
proteoglycan
involv
bind
r
f
rxr
conjug
rxr
conjug
lowest
bind
affin
insert
x
oligoarginin
cpp
reduc
charg
densiti
may
lead
decreas
bind
affin
proteoglycan
despit
lower
cellular
uptak
xbcontain
cpppmo
gener
higher
antisens
activ
cell
nucleu
found
endocytosi
intern
mechan
least
primarili
oligoarginineand
rxr
conjug
indic
differ
uptak
mechan
found
among
conjug
therefor
hypothes
xbcontain
conjug
greater
abil
escap
endosomeslysosom
oligoarginin
conjug
mechan
yet
studi
number
x
residu
affect
nuclear
antisens
activ
toxic
conjug
conjug
x
residu
rx
highest
activ
follow
one
xs
rxr
figur
howev
conjug
toxic
cell
higher
concentr
may
concern
consid
potenti
applic
vivo
deliveri
pmo
replac
xs
bs
decreas
toxic
antisens
activ
combin
xs
sever
b
residu
yield
cpp
detect
toxic
concentr
sever
similar
antisens
activ
rx
think
type
cpp
bs
fewer
xs
offer
balanc
activ
low
toxic
well
stabil
consider
potenti
deliveri
therapeut
ao
investig
toxic
activ
versu
dose
level
cpp
vivo
warrant
surprisingli
replac
larginin
darginin
enhanc
neither
uptak
antisens
activ
oligoarginin
xand
bcontain
conjug
case
rx
replac
actual
caus
small
statist
signific
decreas
activ
observ
differ
result
report
other
found
dcpp
higher
cellular
uptak
lcpp
although
biolog
function
cargo
use
studi
differ
result
may
due
type
size
cargo
cell
line
use
assay
whether
use
dargininecontain
peptid
result
superior
function
activ
vivo
remain
test
attempt
understand
natur
rx
rxr
toxic
appar
two
conjug
caus
littl
immedi
membran
damag
h
treatment
concentr
high
mm
figur
howev
two
conjug
dosedepend
toxic
hr
treatment
shown
leaki
cell
membran
fewer
cell
compar
control
figur
figur
interestingli
replac
xs
bs
rx
abolish
toxic
replac
larginin
darginin
reduc
toxic
rx
figur
found
rx
complet
stabl
peptid
portion
rb
partial
degrad
wherea
peptid
portion
rx
complet
degrad
cell
wonder
whether
differ
toxic
among
rx
rb
rx
conjug
caus
differ
intracellular
stabil
result
metabol
product
rx
produc
toxic
identifi
metabol
product
rx
neither
product
detect
toxic
measur
mtt
assay
data
shown
possibl
cpp
portion
degrad
free
amino
acid
andor
smaller
peptid
fragment
toxic
howev
investig
reveal
neither
free
r
x
alon
combin
caus
cellular
toxic
anoth
possibl
high
hydrophob
x
compar
b
x
combin
posit
charg
arginin
residu
lead
toxic
gener
b
residu
combin
howev
explan
account
differ
toxic
observ
rx
rx
hydrophob
perhap
toxic
rxr
rx
caus
peptid
fragment
could
identifi
mass
spectrometri
unlik
toxic
differ
rx
rx
l
replac
chang
toxic
rxr
figur
substitut
either
one
r
rxr
two
r
rxr
rxr
repeat
neither
reduc
increas
toxic
profil
rxr
point
fulli
understand
mechan
rxr
rx
conjug
toxic
look
forward
studi
topic
serum
effect
activ
conjug
import
issu
consid
potenti
vivo
applic
xbcontain
conjug
still
activ
serum
oligoarginin
conjug
greater
stabil
xbcontain
conjug
serum
enzym
like
factor
contribut
high
activ
loss
activ
high
serum
concentr
make
oligoarginin
cpp
undesir
potenti
therapeut
ao
carrier
summari
found
xbcontain
conjug
superior
conjug
follow
reason
display
higher
activ
cell
nuclei
less
affect
serum
stabl
blood
toxic
xbcontain
cpp
reduc
keep
number
x
residu
still
maintain
reason
deliveri
efficaci
stabil
studi
provid
basi
optim
cpp
sequenc
use
r
r
x
b
residu
interest
reduc
toxic
increas
antisens
activ
like
lead
effect
ao
transport
potenti
therapeut
applic
